Evidence map›Paper›PMID 30030557›Full record

ArticleCancer immunology, immunotherapy : CII2018

Production of a mouse monoclonal IgM antibody that targets the carbohydrate Thomsen-nouveau cancer antigen resulting in in vivo and in vitro tumor killing.

Kevin R Trabbic, Kristopher A Kleski, Mengchao Shi, Jean-Paul Bourgault, Jillian M Prendergast, Daniel T Dransfield, Peter R Andreana

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. A roadmap for translational cancer glycoimmunology at single cell resolution.Journal of experimental & clinical cancer research : CR · 2022
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kevin R TrabbicDepartment of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo, 2801 West Bancroft Street, Wolfe Hall 2232B, Toledo, OH, 43606, USA.
Kristopher A KleskiDepartment of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo, 2801 West Bancroft Street, Wolfe Hall 2232B, Toledo, OH, 43606, USA.
Mengchao ShiDepartment of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo, 2801 West Bancroft Street, Wolfe Hall 2232B, Toledo, OH, 43606, USA.
Jean-Paul BourgaultDepartment of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo, 2801 West Bancroft Street, Wolfe Hall 2232B, Toledo, OH, 43606, USA.
Jillian M PrendergastSiamab Therapeutics, Inc., Newton, MA, 02458, USA.
Daniel T DransfieldSiamab Therapeutics, Inc., Newton, MA, 02458, USA.
Peter R AndreanaDepartment of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo, 2801 West Bancroft Street, Wolfe Hall 2232B, Toledo, OH, 43606, USA. peter.andreana@utoledo.edu.ORCID http://orcid.org/0000-0002-5300-6700
University of Toledo · USSiamab Therapeutics (United States) · US

Funding

Entirely Carbohydrate Vaccine Constructs and Their Application in Probing GlycoimR01CA156661 · NCI · WAYNE STATE UNIVERSITY · PI ANDREANA, PETER R · 2011 to 2015
$1.7M
Lead identification of therapeutic anti-glycan antibodies for cancer therapyR43CA186326 · NCI · SIAMAB THERAPEUTICS, INC. · PI PRENDERGAST, JILLIAN MARIE · 2015 to 2015
$220k
NCI NIH HHS R01 CA156661NCI NIH HHS R43 CA186326
6 · The paper itself

Abstract

The construction of a tumor-associated carbohydrate antigen-zwitterionic polysaccharide conjugate, Thomsen-nouveau-polysaccharide A1 (Tn-PS A1, where Tn = D-GalpNAc), has led to the development of a carbohydrate binding monoclonal antibody named Kt-IgM-8. Kt-IgM-8 was produced via hybridoma from Tn-PS A1 hyperimmunized Jackson Laboratory C57BL/6 mice, splenocytes and the murine myeloma cell line Sp2/0Ag14 with subsequent cloning on methyl cellulose semi-solid media. This in-house generated monoclonal antibody negates binding influenced from peptides, proteins, and lipids and preferentially binds monovalent Tn antigen as noted by ELISA, FACS, and glycan array technologies. Kt-IgM-8 demonstrated in vitro and in vivo tumor killing against the Michigan Cancer Foundation breast cell line 7 (MCF-7). In vitro tumor killing was observed using an LDH assay that measured antibody-induced complement-dependent cytotoxicity and these results were validated in an in vivo passive immunotherapy approach using an MCF-7 cell line-derived xenograft model. Kt-IgM-8 is effective in killing tumor cells at 30% cytotoxicity, and furthermore, it demonstrated approximately 40% reduction in tumor growth in the MCF-7 model.

Indexed as

AnimalsAntigens, Tumor-Associated, CarbohydrateAntineoplastic Agents, ImmunologicalBreast NeoplasmsHumansImmunoglobulin MImmunotoxinsMaleMCF-7 CellsMiceMice, Inbred C57BLMice, SCIDPolysaccharidesXenograft Model Antitumor AssaysAntigens, Tumor-Associated, CarbohydrateAntineoplastic Agents, ImmunologicalImmunoglobulin MImmunotoxinsPolysaccharidesTn antigenComplement-dependent cytotoxicityImmunotherapyMonoclonal antibodyThomsen-nouveauTumor-associated carbohydrate antigensXenograft

Identifiers

PMID30030557
PMCPMC11028060
OpenAlexW2884783264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.